Novartis says EU approves expanded use of Glivec
Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.
View ArticleLonger treatment with cancer drug following removal of GI tumor results in...
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead...
View ArticleRegorafenib active in metastatic GI stromal tumors
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and...
View ArticleClinical trial design supports original accelerated approval of sunitinib for...
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of...
View ArticleExpression, genomic patterns predict sarcoma progression
(HealthDay)—The Complexity Index in Sarcoma (CINSARC) and Genomic Index prognostic signatures are valid independent methods of assessing synovial sarcoma (SS) prognosis, according to a study published...
View ArticleFDA expands approval of Bayer cancer drug (Update)
The U.S. Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that do not respond to other treatments.
View ArticleNew technology spots drugs' early impact on cancer
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and...
View ArticleEORTC led intergroup trial investigates Imatinib failure-free survival in...
Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST....
View ArticleResearchers target 'cell sleep' to lower chances of cancer recurrence
An international research team led by University of Pittsburgh Cancer Institute (UPCI) scientists discovered that by preventing cancer cells from entering a state of cellular sleep, cancer drugs are...
View ArticleLaboratory detective work points to potential therapy for rare,...
University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.
View ArticleOhio State partners with MedVax to bring a cancer peptide vaccine to patients
The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking...
View ArticleNew at-risk group identified for gastrointestinal stromal tumors
Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in...
View ArticleUse of new systemic adjuvant therapy in gastrointestinal tumors increasing
A new study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have...
View ArticleAnticancer drug can spur immune system to fight infection
Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.
View ArticlePatients with gastrointestinal tumors at higher risk of other cancers
Researchers at UC San Diego School of Medicine conducted the first population-based study that characterizes the association and temporal relationship between gastrointestinal stromal tumors (GIST) and...
View ArticleDATECAN initiative publishes guidelines for time-to-event end point...
The DATECAN initiative, Definition for the Assessment of Time-to-event Endpoints in CANcer trials, has published Guidelines for time-to-event end point definitions in breast cancer trials in a recent...
View ArticleThree 'targeted' cancer drugs raise risk of fatal side effects
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer...
View ArticleNew drug overcomes resistance in patients with rare sarcoma
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all...
View ArticleAntibody hinders growth of Gleevec-resistant gastrointestinal tumors in lab...
An antibody that binds to a molecule on the surface of a rare but deadly tumor of the gastrointestinal tract inhibits the growth of the cancer cells in mice, according to researchers at the Stanford...
View ArticleBlood tests can provide fuller picture of mutations in cancer than...
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will...
View ArticleStudy shows certain gastrointestinal tumors associated with higher mortality
Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors (GISTs) are more deadly than previously reported in medical...
View ArticleResearchers identify new drug target for gastrointestinal stromal tumors
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal...
View ArticleLarge-scale cancer gene profiling is feasible but faces barriers
Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of...
View ArticleNew gene fusions and mutations linked to gastrointestinal stromal tumors
In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, with 5,000 to 6,000 new...
View ArticleSmall intestine GIST associated with better prognosis in younger patients
Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can...
View ArticleStudy shows strong long-term survival rates for patients with GIST
Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the...
View ArticleNew England Journal of Medicine publishes long-term results of Gleevec for...
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec, as an oral therapy for patients with chronic myeloid leukemia, or CML.
View ArticleDeficiencies in repair of DNA identified in many types of solid tumors
A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.
View ArticleGIST tumors linked to NF1 mutations, genetic testing needed
Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel,...
View Article
